Advance the clinical development of emodepside as an anti-parasitic macrofilaricidal treatment
current phase of drug development
updated 29 Feb 2020
Originating from the Japanese pharmaceutical company Astellas, emodepside has been developed and commercialized by Bayer Animal Health as an anti-helminthic veterinary drug for cats and dogs. DNDi has a collaboration agreement with Bayer AG to jointly develop emodepside for the treatment of onchocerciasis. Bayer provides the active ingredient emodepside to DNDi, and DNDi is responsible for the clinical development of emodepside and Bayer for the pre-clinical and pharmaceutical development, as well as for registration, manufacturing, and distribution of the drug.
News and press releases
Get our latest news, personal stories, research articles, and job opportunities.